AMS to develop new woundcare range
CHESHIRE-based Advanced Medical Solutions is to develop a new range of foam-based advanced woundcare dressings after signing a licencing deal with pharmaceuticals company Sinclair IS Pharma.
AIM-listed, Winsford-based AMS has signed a licensing agreement for Sinclair IS’s Delmopinol anti-biofilm technology.
Bacterial biofilms are widely recognised as a major cause of microbial resistance to current treatments. Complications with infections are known to delay the wound healing process and can be fatal.
AMS said it had been working with a number of universities to explore the potential of Delmopinol as an anti-biofilm agent in conjunction with one of its own anti-microbial woundcare dressings.
The results have been positive, so far, and consequently the two parties have signed an agreement allowing AMS to conduct further research and development and feasibility testing for up to a maximum of six months.
Should all go well at the end of this period, AMS has the right to exclusively license the worldwide patent rights from Sinclair IS for the new use of Delmopinol in foam-based Advanced Woundcare dressings.
AMS chief executive Chris Meredith said: “As we have previously indicated, we believe the future of advanced woundcare lies in antimicrobial and ‘active’ wound dressings.
“In this regard, our R&D programme has been looking into ways to control biofilms within chronic wounds, in order to further improve the efficacy of our dressings.
“Whilst there is still work to do to confirm its feasibility, indications so far are encouraging that a combination of Delmopinol and our own anti-microbial foam technologies could provide an effective new range of dressings to combat biofilms. We are delighted to be working with Sinclair IS Pharma on this initiative.”
